← Leaderboards
Mary Bastida
Sri International
$1,457,758
Attributed
$1,457,758
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $962.4K · FY2019–23$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,457,758 · 2
By mechanism
N01$1,457,758 · 2
Top collaborators
No co-investigators on record.
Most similar at Sri International
Same institution · by research overlap
- Jon Carl Mirsalis$108,012,322
- Jon Mirsalis$56,020,705
- Polly Chang$121,906,628
- Toufan Parman$25,866,968
- Katherine Baughman$4,521,467
Others in their field
Other Emerging Leaders on “In Vitro”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Leonard Freedmand · Leidos Biomedical Research, Inc.$68,796,314
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$41,541,738
- John Damon Chodera · Sloan-Kettering Inst Can Research$34,949,884
- Tony Moody · Duke University$34,777,314
Research focus
In VitroIn VivoEvaluationLeadPathogenChemistryToxinProgramsSafetyServicesTherapeutic DevelopmentToxicologyDrug KineticsPre-ClinicalCommunicable DiseasesDevelopment PlansProduct DevelopmentInterventional Agent DevelopmentMicrobiologySupport ContractsStability TestingTaenia SoliumAntimicrobial ResistanceAntiparasitic Agents
Grant awards (8)
Task C04: Stability testing of an antiparasitic therapeutic$54,021
N01 · FY2023 · AI · contact PI
IN VITRO METABOLISM AND NON-CLINICAL ADME STUDIES IDIQ CONTRACT. POP 9/27/21-9/26/26. NTE $3.5 MILLION. TASK ORDER 03 OBLIGATED IN THE AMOUNT OF $136$165,694
N01 · FY2022 · DA · contact PI
Task C04: Stability testing of an antiparasitic therapeutic$21,685
N01 · FY2022 · AI · contact PI
Task B21: Drug Development for Enterobacteriaciae$143,126
N01 · FY2021 · AI · contact PI
IN VITRO METABOLISM AND NON-CLINICAL ADME STUDIES IDIQ CONTRACT. POP 9/27/21-9/26/26. NTE $3.5 MILLION. FIRST TASK ORDER 01 OBLIGATED IN THE AMOUNT O$89,708
N01 · FY2021 · DA · contact PI
Task C04: Stability testing of an antiparasitic therapeutic$21,174
N01 · FY2021 · AI · contact PI
Task D02: Pre-Clinical Pharmacokinetic Services$915,076
N01 · FY2019 · AI · contact PI
Task C04: Continuation of stability testing of an antiparisitic therapeutics$47,274
N01 · FY2019 · AI · contact PI